{"id":"ferric-carboxymaltose","rwe":[{"pmid":"41881665","year":"2026","title":"Parenteral iron-Does it increase infection risk?","finding":"","journal":"Vox sanguinis","studyType":"Clinical Study"},{"pmid":"41865415","year":"2026","title":"Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial.","finding":"","journal":"The Lancet. Global health","studyType":"Clinical Study"},{"pmid":"41849242","year":"2026","title":"Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia.","finding":"","journal":"Blood","studyType":"Clinical Study"},{"pmid":"41808693","year":"2026","title":"Integrating a single-dose intravenous iron therapy (ferric carboxymaltose) for maternal anaemia in Nigeria: Insights from stakeholder engagement.","finding":"","journal":"Journal of public health in Africa","studyType":"Clinical Study"},{"pmid":"41771608","year":"2026","title":"Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study.","finding":"","journal":"Nefrologia","studyType":"Clinical Study"}],"_fda":{"id":"a092ebb6-505b-464f-9669-194a913ff8e5","set_id":"517b4a19-45b3-4286-9f6a-ced4e10447de","openfda":{"unii":["6897GXD6OE"],"route":["INTRAVENOUS"],"rxcui":["1435169","1435174","2552400","2552401","2602296","2602297"],"spl_id":["a092ebb6-505b-464f-9669-194a913ff8e5"],"brand_name":["Injectafer"],"spl_set_id":["517b4a19-45b3-4286-9f6a-ced4e10447de"],"package_ndc":["0517-0650-01","0517-0620-01","0517-0602-01"],"product_ndc":["0517-0602","0517-0650","0517-0620"],"generic_name":["FERRIC CARBOXYMALTOSE INJECTION","FERRIC CARBOXYMALTOSE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FERRIC CARBOXYMALTOSE"],"manufacturer_name":["American Regent, Inc."],"application_number":["NDA203565"],"is_original_packager":[true]},"version":"29","pregnancy":["8.1 Pregnancy Risk Summary Parenteral iron administration may be associated with hypersensitivity reactions [ see Warnings and Precautions ( 5.1 )], which may have serious consequences, such as fetal bradycardia ( see Clinical Considerations ). Advise pregnant women of the potential risk to a fetus. Published studies and available data from postmarketing reports with intravenous Injectafer are insufficient to assess the risk of major birth defects and miscarriage. There are risks to the mother and fetus associated with untreated IDA in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see Clinical Considerations). In animal reproduction studies, administration of ferric carboxymaltose to rabbits during the period of organogenesis caused adverse developmental outcomes including fetal malformations and increased implantation loss at maternally toxic doses of approximately 12% to 23% of the human weekly dose of 750 mg (based on body surface area). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Untreated IDA in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight. Fetal/Neonatal adverse reactions Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products (such as Injectafer) which may cause fetal bradycardia, especially during the second and third trimester. Data Human Data Published data from randomized controlled studies, prospective observational studies and retrospective studies on the use of ferric carboxymaltose in pregnant women have not reported an association with intravenous ferric carboxymaltose and major birth defects and miscarriage. However, these studies cannot establish or exclude the absence of any drug-related risk during pregnancy. Animal Data Administration of ferric carboxymaltose to rats as a one-hour intravenous infusion up to 30 mg/kg/day iron on gestation days 6 to 17 did not result in adverse embryonic or fetal findings. This daily dose in rats is approximately 40% of the human weekly dose of 750 mg based on body surface area. In rabbits, ferric carboxymaltose was administered as a one-hour infusion on gestation days 6 to 19 at iron doses of 4.5, 9, 13.5, and 18 mg/kg/day. Malformations were seen starting at the daily dose of 9 mg/kg (23% of the human weekly dose of 750 mg). Spontaneous abortions occurred starting at the daily iron dose of 4.5 mg/kg (12% of the human weekly dose of 750 mg based on body surface area). Pre-implantation loss was at the highest dose. Adverse embryonic or fetal effects were observed in the presence of maternal toxicity. A pre- and post-natal development study was conducted in rats at intravenous doses up to 18 mg/kg/day of iron (approximately 23% of the weekly human dose of 750 mg based on body surface area). There were no adverse effects on survival of offspring, their behavior, sexual maturation or reproductive parameters."],"overdosage":["10 OVERDOSAGE Excessive dosages of Injectafer may lead to accumulation of iron in storage sites potentially leading to hemosiderosis. A patient who received Injectafer 18,000 mg over 6 months developed hemosiderosis with multiple joint disorder, walking disability, and asthenia. In the postmarketing setting, hypophosphatemic osteomalacia has been reported in patients who have received repeated high-cumulative courses of Injectafer."],"description":["11 DESCRIPTION Ferric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III)-hydroxide 4(R)-(poly-(1→4)- O -α-D-glucopyranosyl)-oxy-2(R),3(R),5(R),6-tetrahydroxy-hexanoate. It has a relative molecular weight of approximately 150,000 Da corresponding to the following empirical formula: [FeO x (OH) y (H 2 O) z ] n [{(C 6 H 10 O 5 ) m (C 6 H 12 O 7 )} l ] k , where n ≈ 10 3 , m ≈ 8, l ≈ 11, and k ≈ 4 ( l represents the mean branching degree of the ligand). The chemical structure is presented below: Injectafer (ferric carboxymaltose injection) is a dark brown, sterile, aqueous, isotonic colloidal solution for intravenous injection. Each mL contains 50 mg iron as ferric carboxymaltose in water for injection. Injectafer is available in 2 mL, 15 mL and 20 mL single-dose vials. Sodium hydroxide and/or hydrochloric acid may have been added to adjust the pH to 5.0-7.0. Vial closure is not made with natural rubber latex. New structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Injectafer (ferric carboxymaltose injection) is a dark brown, non-transparent, sterile, aqueous solution. NDC 0517-0602-01 100 mg iron/2 mL Single-Dose Vial Individually Boxed NDC 0517-0650-01 750 mg iron/15 mL Single-Dose Vial Individually Boxed NDC 0517-0620-01 1,000 mg iron/20 mL Single-Dose Vial Individually Boxed Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See the USP controlled room temperature.] Do not freeze."],"geriatric_use":["8.5 Geriatric Use Of the 1,775 subjects in clinical studies of Injectafer, 50% were 65 years and over, while 25% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Injectafer for IDA in pediatric patients aged 1 year and older who have normal kidney function and have either intolerance to oral iron or have had unsatisfactory response to oral iron have been established. Use of Injectafer for this indication in this age group is supported by evidence from adequate and well-controlled studies of Injectafer in adults with additional pharmacodynamic and safety data in pediatric patients aged 1 year and older [ see Adverse Reactions ( 6.1 ) and Clinical Pharmacology ( 12.3 )]. Safety and effectiveness of Injectafer have not been established in pediatric patients less than 1 year of age with IDA. Safety and effectiveness of Injectafer have not been established to improve exercise capacity in pediatric patients with ID and symptomatic heart failure."],"effective_time":"20250101","clinical_studies":["14 CLINICAL STUDIES 14.1 Iron Deficiency Anemia The safety and efficacy of Injectafer for treatment of IDA were evaluated in two randomized, open-label, controlled clinical trials (Trial 1 and Trial 2). In these two trials, Injectafer was administered at a dose of 15 mg/kg body weight up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1,500 mg of iron. Trial 1: Iron Deficiency Anemia in Patients Who Are Intolerant to Oral Iron or Have Had Unsatisfactory Response to Oral Iron Trial 1: A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients with Iron Deficiency Anemia (IDA), (NCT00982007) was a randomized, open-label, controlled clinical study in patients with IDA who had an unsatisfactory response to oral iron (Cohort 1) or who were intolerant to oral iron (Cohort 2) during the 14-day oral iron run-in period. Inclusion criteria prior to randomization included hemoglobin (Hb) <12 g/dL, ferritin ≤100 ng/mL or ferritin ≤300 ng/mL when transferrin saturation (TSAT) ≤30%. Cohort 1 subjects were randomized to Injectafer or oral iron for 14 more days. Cohort 2 subjects were randomized to Injectafer or another IV iron per standard of care [90% of subjects received iron sucrose]. The mean age of study patients was 43 years (range, 18 to 94); 94% were female; 42% were Caucasian, 32% were African American, 24% were Hispanic, and 2% were other races. The primary etiologies of IDA were heavy uterine bleeding (47%) and gastrointestinal disorders (17%). Table 5 shows the baseline and the change in hemoglobin from baseline to highest value between baseline and Day 35 or time of intervention. Table 5. Mean Change in Hemoglobin From Baseline to the Highest Value Between Day 35 or Time of Intervention (Modified Intent‑to‑Treat Population) Hemoglobin (g/dL) Mean (SD) Cohort 1 Cohort 2 Injectafer (N=244) Oral Iron (N=251) Injectafer (N=245) IV SC a (N=237) Baseline 10.6 (1.0) 10.6 (1.0) 9.1 (1.6) 9.0 (1.5) Highest Value 12.2 (1.1) 11.4 (1.2) 12.0 (1.2) 11.2 (1.3) Change (from baseline to highest value) 1.6 (1.2) 0.8 (0.8) 2.9 (1.6) 2.2 (1.3) p-value 0.001 0.001 SD=standard deviation; a Intravenous iron per standard of care Increases from baseline in mean ferritin (264.2 ± 224.2 ng/mL in Cohort 1 and 218.2 ± 211.4 ng/mL in Cohort 2), and transferrin saturation (13 ± 16% in Cohort 1 and 20 ± 15% in Cohort 2) were observed at Day 35 in Injectafer-treated patients. Trial 2: Iron Deficiency Anemia in Patients with Non-Dialysis Dependent Chronic Kidney Disease Trial 2: REPAIR-IDA, Randomized Evaluation of efficacy and safety of Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Impaired Renal function, (NCT00981045) was a randomized, open-label, controlled clinical study in patients with non-dialysis dependent chronic kidney disease. Inclusion criteria included hemoglobin (Hb) ≤11.5 g/dL, ferritin ≤ 100 ng/mL or ferritin ≤300 ng/mL when transferrin saturation (TSAT) ≤ 30%. Study patients were randomized to either Injectafer or Venofer. The mean age of study patients was 67 years (range, 19 to 101); 64% were female; 54% were Caucasian, 26% were African American, 18% Hispanics, and 2% were other races. Table 6 shows the baseline and the change in hemoglobin from baseline to highest value between baseline and Day 56 or time of intervention. Table 6. Mean Change in Hemoglobin From Baseline to the Highest Value Between Baseline and Day 56 or Time of Intervention (Modified Intent‑to‑Treat Population) Hemoglobin (g/dL) Mean (SD) Injectafer (N=1,249) Venofer (N=1,244) Baseline 10.3 (0.8) 10.3 (0.8) Highest Value 11.4 (1.2) 11.3 (1.1) Change (from baseline to highest value) 1.1 (1.0) 0.9 (0.92) Treatment Difference (95% CI) 0.21 (0.13, 0.28) Increases from baseline in mean ferritin (734.7 ± 337.8 ng/mL) and transferrin saturation (30 ± 17%) were observed prior to Day 56 in Injectafer-treated patients. 14.2 Iron Deficiency in Heart Failure Trial 3: FER-CARS-05 (CONFIRM-HF) was a randomized, double-blind, placebo-controlled, study in patients with iron deficiency and chronic heart failure with left ventricular ejection fraction of < 45% and New York Heart Association (NYHA) class II/III to determine whether intravenous Injectafer improves exercise capacity measured as change from baseline to 24 weeks in 6-minute walk distance (6MWD). Iron deficiency was defined as serum ferritin <100 ng/mL or 100 to 300 ng/mL with TSAT <20%. Patients with Hb of ≥ 15 g/dl were excluded. Of the 304 patients, 150 were randomized to Injectafer and 151 to placebo. The median age of study patients was 71 years (range, 35 to 88); 46% were female; 99% were Caucasian. At baseline, mean (SD) Hb was 12 g/dl (1.4), ferritin 57 ng/ml (45), TSAT 19 % (13.7), LVEF 37% (7), brain natriuretic peptide 770 pg/mL (973); and 57 and 43% were classified as NYHA class II and III, respectively. At baseline, 95% of patients were treated with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), 91% with beta-blocker, 59% with aldosterone antagonists, and 90% with diuretic. The mean change in 6MWD from Baseline to Week 24 in Injectafer-treated patients was 18 meters (95% CI 4, 32), and placebo-treated patients was -7 meters (95% CI -21, 7), with between group difference of 25 meters (7, 43), p-value 0.007, favoring Injectafer. Results were generally similar within age and sex subgroups. In Injectafer-treated patients, change from Baseline to Week 24 in serum ferritin was 269 ng/mL (229, 309), in TSAT was 9% (7, 11), and in Hb was 0.6 g/dL (0.3, 0.8)."],"pharmacodynamics":["12.2 Pharmacodynamics Using positron emission tomography (PET) it was demonstrated that red cell uptake of 59 Fe and 52 Fe from Injectafer ranged from 61% to 99%. In patients with iron deficiency, red cell uptake of radiolabeled iron ranged from 91% to 99% at 24 days after Injectafer dose. In patients with renal anemia, red cell uptake of radiolabeled iron ranged from 61% to 84% at 24 days after Injectafer dose."],"pharmacokinetics":["12.3 Pharmacokinetics After administration of a single dose of Injectafer of 100 to 1,000 mg of iron in iron deficient adult patients, maximum iron concentration of 37 µg/mL to 333 µg/mL were obtained respectively after 15 minutes to 1.21 hours post dose. The volume of distribution was estimated to be 3 L. The iron injected or infused was rapidly cleared from the plasma, the terminal half-life ranged from 7 to 12 hours. Renal elimination of iron was negligible. After administration of a single dose of Injectafer 15 mg/kg in pediatric patients 1-17 years of age, the maximum concentrations ranged between 124 and 418.1 μg/mL and the median time to maximum concentration was 7 minutes. The elimination half-life of Injectafer in pediatric patients was approximately 9.7 hours. The total median 72-hour exposure (AUC 0-72h ) after a single dose of Injectafer 15 mg/kg in pediatric patients was 4,529.7 μg∙h/mL while the median exposure after a single dose of 1,000 mg in adults was 5,875.3 μg∙h/mL."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Hypophosphatemia [see Warnings and Precautions ( 5.2 )] Hypertension [see Warnings and Precautions ( 5.3 )] Laboratory Test Alterations [see Warnings and Precautions ( 5.4 )] The most common adverse reactions in adult patients (>2%) are nausea, hypertension, flushing, injection site reactions, erythema, hypophosphatemia, and dizziness. ( 6.1 ) The most common adverse reactions in pediatric patients (≥4%) are hypophosphatemia, injection site reactions, rash, headache, and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact American Regent at 1-800-734-9236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice. Adults In two randomized clinical studies [Studies 1 and 2, see Clinical Studies ( 14 ) ], a total of 1,775 patients were exposed to Injectafer 15 mg/kg body weight up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1,500 mg of iron. Adverse reactions reported by ≥1% of treated patients are shown in the following table. Table 2. Adverse reactions reported in ≥1% of Study Patients in Clinical Trials 1 and 2 Injectafer (N=1,775) % Pooled Comparators a (N=1,783) % Oral iron (N=253) % Nausea 7.2 2 1.2 Hypertension* 4 2 0.4 Flushing* 4 0.2 0 Injection site reactions* 3 3.2 0 Erythema* 3 0.6 0 Hypophosphatemia 2.1 0.1 0 Dizziness* 2.1 1.3 0.4 Vomiting 2 1 0.4 Injection Site Discoloration** 1.4 0.3 0 Headache* 1.3 1.2 0.4 Hepatic enzyme increased* 1.2 0.2 0 Dysgeusia* 1.2 2.1 0 Hypotension 1 2 0 Rash* 1 0.3 0 Constipation 0.5 0.9 3.2 a Includes oral iron and all formulations of IV iron other than Injectafer *Grouped Terms: Hypertension includes hypertension, blood pressure increased, and hypertensive crisis. Flushing includes flushing and hot flush. Injection site reactions include injection site extravasation, injection site discoloration, injection site pain, injection site irritation, injection site bruising, injection site reaction, injection site discomfort, injection site erythema, injection site hematoma, injection site hemorrhage, injection site pruritus, injection site rash, and injection site swelling. Erythema includes erythema and injection site erythema. Dizziness includes dizziness, balance disorder, and vertigo. **Injection site discoloration was also included in the injection site local administration reactions grouped term. Headache includes headache and migraine. Hepatic enzyme increased includes alanine aminotransferase increased and aspartate aminotransferase increased. Dysgeusia includes dysgeusia and ageusia. Rash includes rash, urticaria, skin exfoliation, blister, erythema multiforme, injection site rash, rash maculo-papular, and rash pruritic. Other adverse reactions reported by ≥0.5% of treated patients include abdominal pain, diarrhea, gamma glutamyl transferase increased, paresthesia, and sneezing. Transient decreases in laboratory blood phosphorus levels (< 2 mg/dL) have been observed in 27% (440/1,638) of patients in clinical trials. Pooled data from two Phase 3 studies 1VIT09030 (NCT00981045) and 1VIT09031 (NCT00982007) with a dosing regimen of Injectafer 15 mg/kg up to a maximum of 750 mg x 2 doses to a cumulative dose of 1,500 mg of iron were analyzed to compare rates of adverse reactions in two Phase 3 parallel group studies 1VIT07017 (NCT00548860) and 1VIT07018 (NCT00548691) with a dosing regimen of Injectafer 15 mg/kg up to a maximum of 1,000 mg single dose (Table 3). Table 3. Adverse Reactions (≥1% in any Treatment Group) In Patients Receiving Two Doses of 15 mg/kg to a Maximum of 750 mg to a Cumulative Dose of 1,500 mg or a Single Dose of Injectafer 15 mg/kg to a Maximum of 1,000 mg. Injectafer 15 mg/kg to a maximum of 750 mg x 2 doses to a cumulative dose of 1,500 mg Injectafer 15 mg/kg to a maximum of 1,000 mg single dose IVIT09030 and IVIT09031 b (N=1,775) % IVIT07017 and IVIT07018 a (N=1,200) % Any Adverse Reaction 24 12 Injection site reactions* 3 4 Injection site extravasation** 0.2 2 Hepatic enzyme increased* 1.2 1.2 Rash* 1 1.2 Headache* 1.3 1 Dizziness* 2.1 1 Dysgeusia* 1.2 1 Nausea 7.2 1 Hypertension* 4 1 Hypophosphatemia 2.1 1 Erythema* 3 0.3 Flushing* 4 0.3 Vomiting 2 0.2 Injection site discoloration** 1.4 <0.1 Hypotension 1 <0.1 ab Included studies 1VIT07017, 1VIT07018, 1VIT09030 and 1VIT09031 *Grouped Terms **Injection site extravasation and injection site discoloration were also included in the injection site reactions grouped term. Pediatric Patients The safety of Injectafer in pediatric patients was evaluated in study 1VIT17044 (NCT03523117; Study 3). Study 1VIT17044 was a randomized, active-controlled study in which 40 patients (1 to 12 years of age: 10 patients, 12 to 17 years of age: 30 patients) received Injectafer 15 mg/kg to a maximum single dose of 750 mg (whichever was smaller) on Days 0 and 7 for a maximum total dose of 1,500 mg; 38 patients evaluable for safety in the control arm received an age-dependent formulation of oral ferrous sulfate for 28 days. The median age of patients who received Injectafer was 14.5 years (range, 1-17); 83% were female; 88% White and 13% Black. The most common adverse reactions (≥4%) were hypophosphatemia, injection site reactions, rash, headache, and vomiting. Table 4 summarizes the adverse reactions in Study 3. Table 4. Adverse Reactions of any Grade in Pediatric Patients Receiving Injectafer in Study 3 Injectafer (N=40) % Oral Ferrous Sulfate (N=38) % Any Adverse Reactions 35 26 Hypophosphatemia* 13 0 Injection site reactions* 8 0 Rash* 8 0 Headache 5 3 Vomiting 5 3 Nasopharyngitis 3 5 Flushing 3 0 Gastrointestinal infections 3 0 Liver function test increased 3 0 Platelet count decreased 3 0 White blood cell count decreased 3 0 *Grouped Terms Injection site reactions include infusion site hematoma, infusion site hypoesthesia and injection site pain. Hypophosphatemia includes hypophosphatemia and blood phosphorus decreased. Rash includes rash, exanthema and urticaria. Patients with Iron Deficiency and Heart Failure The safety of Injectafer was evaluated in adult patients with iron deficiency and heart failure in randomized controlled trials FAIR-HF (NCT00520780), CONFIRM-HF (NCT01453608) and AFFIRM-AHF (NCT02937454) in which 1,016 patients received Injectafer versus 857 received placebo. The overall safety profile of Injectafer was consistent across the studied indications. 6.2 Post-marketing Experience The following adverse reactions have been identified during post approval use of Injectafer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported from the post-marketing spontaneous reports with Injectafer: Cardiac disorders: Tachycardia General disorders and administration site conditions: Chest discomfort, chills, pyrexia Metabolism and nutrition disorders: Hypophosphatemia Musculoskeletal and connective tissue disorders: Arthralgia, back pain, hypophosphatemic osteomalacia Nervous system disorders: Syncope Respiratory, thoracic and mediastinal disorders: Dyspnea Skin and subcutaneous tissue disorders: Angioedema, erythema, pruritus, urticaria Pregnancy: Fetal bradycardia"],"contraindications":["4 CONTRAINDICATIONS Injectafer is contraindicated in patients with a history of hypersensitivity to Injectafer or any of its components [see Warnings and Precautions ( 5.1 ) ]. Hypersensitivity to Injectafer or any of its inactive components."],"mechanism_of_action":["12.1 Mechanism of Action Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron."],"recent_major_changes":["RECENT MAJOR CHANGES Warnings and Precautions, Symptomatic Hypophosphatemia. (5.2) 02/2020 Warnings and Precautions, Symptomatic Hypophosphatemia ( 5.2 ) 11/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron. 12.2 Pharmacodynamics Using positron emission tomography (PET) it was demonstrated that red cell uptake of 59 Fe and 52 Fe from Injectafer ranged from 61% to 99%. In patients with iron deficiency, red cell uptake of radiolabeled iron ranged from 91% to 99% at 24 days after Injectafer dose. In patients with renal anemia, red cell uptake of radiolabeled iron ranged from 61% to 84% at 24 days after Injectafer dose. 12.3 Pharmacokinetics After administration of a single dose of Injectafer of 100 to 1,000 mg of iron in iron deficient adult patients, maximum iron concentration of 37 µg/mL to 333 µg/mL were obtained respectively after 15 minutes to 1.21 hours post dose. The volume of distribution was estimated to be 3 L. The iron injected or infused was rapidly cleared from the plasma, the terminal half-life ranged from 7 to 12 hours. Renal elimination of iron was negligible. After administration of a single dose of Injectafer 15 mg/kg in pediatric patients 1-17 years of age, the maximum concentrations ranged between 124 and 418.1 μg/mL and the median time to maximum concentration was 7 minutes. The elimination half-life of Injectafer in pediatric patients was approximately 9.7 hours. The total median 72-hour exposure (AUC 0-72h ) after a single dose of Injectafer 15 mg/kg in pediatric patients was 4,529.7 μg∙h/mL while the median exposure after a single dose of 1,000 mg in adults was 5,875.3 μg∙h/mL."],"indications_and_usage":["1 INDICATIONS AND USAGE Injectafer is indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Injectafer is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of each administration. ( 5.1 ) Symptomatic Hypophosphatemia: Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment. ( 5.2 ) Hypertension: Monitor patients closely for signs and symptoms of hypertension following each Injectafer administration. ( 5.3 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions [see Adverse Reactions ( 6.1 , 6 .2 )]. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1,775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1,775) of these subjects. 5.2 Symptomatic Hypophosphatemia Symptomatic hypophosphatemia with serious outcomes including osteomalacia and fractures requiring clinical intervention has been reported in patients treated with Injectafer in the post-marketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. However, symptomatic hypophosphatemia has been reported after one dose. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, inflammatory bowel disease, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, malnutrition, and hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu syndrome). In most cases, hypophosphatemia resolved within three months. Correct pre-existing hypophosphatemia prior to initiating therapy with Injectafer. Monitor serum phosphate levels in patients at risk for chronic low serum phosphate. Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a second course of therapy within three months [see Dosage and Administration ( 2.3 )] . Treat hypophosphatemia as medically indicated. 5.3 Hypertension In clinical studies, hypertension was reported in 4% (67/1,775) of subjects in clinical trials 1 and 2. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1,775) of subjects in these two clinical trials. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration [see Dosage and Administration ( 2 )]. 5.4 Laboratory Test Alterations In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer."],"clinical_studies_table":["
Hemoglobin (g/dL)Mean (SD)Cohort 1Cohort 2
Injectafer (N=244)Oral Iron (N=251)Injectafer (N=245)IV SCa (N=237)
Baseline 10.6 (1.0)10.6 (1.0)9.1 (1.6)9.0 (1.5)
Highest Value12.2 (1.1)11.4 (1.2)12.0 (1.2)11.2 (1.3)
Change (from baseline to highest value)1.6 (1.2)0.8 (0.8)2.9 (1.6)2.2 (1.3)
p-value0.0010.001
","
Hemoglobin (g/dL) Mean (SD)Injectafer (N=1,249)Venofer (N=1,244)
Baseline10.3 (0.8)10.3 (0.8)
Highest Value 11.4 (1.2)11.3 (1.1)
Change (from baseline to highest value)1.1 (1.0)0.9 (0.92)
Treatment Difference (95% CI)0.21 (0.13, 0.28)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenicity studies have not been performed with ferric carboxymaltose. Ferric carboxymaltose was not genotoxic in the following genetic toxicology studies: in vitro microbial mutagenesis (Ames) assay, in vitro chromosome aberration test in human lymphocytes, in vitro mammalian cell mutation assay in mouse lymphoma L5178Y/TK+/- cells, in vivo mouse micronucleus test at single intravenous doses up to 500 mg/kg. In a combined male and female fertility study, ferric carboxymaltose was administered intravenously over one hour to male and female rats at iron doses of up to 30 mg/kg. Animals were dosed 3 times per week (on Days 0, 3, and 7). There was no effect on mating function, fertility or early embryonic development. Based on body surface area, the dose of 30 mg/kg in animals is approximately 40% of the human dose of 750 mg."],"adverse_reactions_table":["
Injectafer (N=1,775) %Pooled Comparatorsa (N=1,783) %Oral iron (N=253) %
Nausea7.221.2
Hypertension*420.4
Flushing*40.20
Injection site reactions*33.20
Erythema*30.60
Hypophosphatemia 2.10.10
Dizziness*2.11.30.4
Vomiting210.4
Injection Site Discoloration**1.40.30
Headache*1.31.20.4
Hepatic enzyme increased*1.20.20
Dysgeusia*1.22.10
Hypotension120
Rash*10.30
Constipation0.50.93.2
","
Injectafer 15 mg/kg to a maximum of 750 mg x 2 doses to a cumulative dose of 1,500 mgInjectafer 15 mg/kg to a maximum of 1,000 mg single dose
IVIT09030 and IVIT09031b (N=1,775)%IVIT07017 and IVIT07018a(N=1,200)%
Any Adverse Reaction2412
Injection site reactions* 34
Injection site extravasation**0.22
Hepatic enzyme increased* 1.21.2
Rash* 11.2
Headache*1.31
Dizziness* 2.11
Dysgeusia* 1.21
Nausea 7.21
Hypertension*41
Hypophosphatemia2.11
Erythema*30.3
Flushing*40.3
Vomiting 20.2
Injection site discoloration**1.4<0.1
Hypotension1<0.1
","
Injectafer (N=40) %Oral Ferrous Sulfate (N=38) %
Any Adverse Reactions3526
Hypophosphatemia*130
Injection site reactions*80
Rash*80
Headache53
Vomiting53
Nasopharyngitis35
Flushing30
Gastrointestinal infections30
Liver function test increased30
Platelet count decreased30
White blood cell count decreased30
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information) and discuss with the patient the etiology of the iron deficiency anemia and the patient’s iron deficiency anemia treatment options. Prior History of Reactions to Parenteral Iron Products Question patients regarding any prior history of reactions to parenteral iron products [see Warnings and Precautions ( 5.1 )] . Serious Hypersensitivity Reactions Advise patients to report any signs and symptoms of hypersensitivity that may develop during and following Injectafer administration, such as rash, itching, dizziness, lightheadedness, swelling, and breathing problems [ see Warnings and Precautions ( 5.1 )] . Symptomatic Hypophosphatemia Advise patients to report any signs or symptoms of hypophosphatemia such as fatigue, muscle weakness or pain, bone and joint pain, or bone fractures [see Warnings and Precautions ( 5.2 )] . Pregnancy Advise pregnant women about the risk of hypersensitivity reactions which may have serious consequences for the fetus. Advise patients who may become pregnant to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations ( 8.1 )]. Injectafer is manufactured under license from Vifor (International) Inc, Switzerland. Distributed by : RQ1052-I ARI Logo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For patients weighing 50 kg or more, the recommended dosage is Injectafer 750 mg intravenously in two doses separated by at least 7 days for a total cumulative dose of 1,500 mg of iron per course. For adult patients weighing 50 kg or more, an alternative dose of Injectafer 15 mg/kg body weight up to a maximum of 1,000 mg intravenously may be administered as a single-dose per course. ( 2.1 ) For patients weighing less than 50 kg, the recommended dosage is Injectafer 15 mg/kg body weight intravenously in two doses separated by at least 7 days per course. ( 2.1 ) See Section 2.1, Table 1 for dosage in patients with iron deficiency and heart failure. ( 2.1 ) Injectafer treatment may be repeated if IDA or iron deficiency in heart failure reoccurs. ( 2.3 ) 2.1 Recommended Dosage Recommended Dosage for Treatment of Iron Deficiency Anemia For patients weighing 50 kg or more, the recommended dosage is: Injectafer 750 mg intravenously in two doses separated by at least 7 days for a total cumulative dose of 1,500 mg of iron per course. In adult patients, Injectafer 15 mg/kg body weight up to a maximum of 1,000 mg intravenously may be administered as a single-dose per course. For patients weighing less than 50 kg, the recommended dosage is Injectafer 15 mg/kg body weight intravenously in two doses separated by at least 7 days per course. Recommended Dosage in Patients with Iron Deficiency with Heart Failure See Table 1 for recommended dosage for treatment of iron deficiency in patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Table 1: Recommended Dosage in Patients with Iron Deficiency with Heart Failure Weight less than 70 kg Weight 70 kg or more Hb (g/dL) Hb (g/dL) < 10 10 to 14 > 14 to < 15 < 10 10 to 14 > 14 to < 15 Day 1 1,000 mg 1,000 mg 500 mg 1,000 mg 1,000 mg 500 mg Week 6 500 mg No dose No dose 1,000 mg 500 mg No dose Administer a maintenance dose of 500 mg at 12, 24 and 36 weeks if serum ferritin <100 ng/mL or serum ferritin 100-300 ng/mL with transferrin saturation <20%. There are no data available to guide dosing beyond 36 weeks or with Hb ≥15 g/dL. 2.2 Preparation and Administration Administer Injectafer intravenously, either as an undiluted slow intravenous push or by infusion. When administered via infusion, dilute up to 1,000 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes. When added to an infusion bag containing 0.9% sodium chloride injection, USP, at concentrations ranging from 2 to 4 mg of iron per mL, Injectafer solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL. Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Injectafer is intended for a single dose. When administering Injectafer 500 or 750 mg as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. For Injectafer 1,000 mg, administer as a slow intravenous push over 15 minutes. Avoid extravasation of Injectafer since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Injectafer administration at that site. Discard unused portion. 2.3 Repeat Treatment Monitoring Safety Assessment Injectafer treatment may be repeated if IDA or iron deficiency in heart failure reoccurs. Check serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment or for any patient who receives a repeat course of treatment within three months [see Warnings and Precautions ( 5.2 )]. Treat hypophosphatemia as medically indicated."],"spl_product_data_elements":["Injectafer Ferric Carboxymaltose Injection FERRIC CARBOXYMALTOSE FERRIC CATION Injectafer Ferric Carboxymaltose FERRIC CARBOXYMALTOSE FERRIC CATION Injectafer Ferric Carboxymaltose Injection FERRIC CARBOXYMALTOSE FERRIC CATION"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 50 mg/mL, dark brown, non-transparent, sterile, aqueous solution. 100 mg iron/2 mL single-dose vial 750 mg iron/15 mL single-dose vial 1,000 mg iron/20 mL single-dose vial Injection: 50 mg/mL 100 mg iron/2 mL single-dose vial 750 mg iron/15 mL single-dose vial 1,000 mg iron/20 mL single-dose vial"],"spl_patient_package_insert":["Patient Information INJECTAFER ( in-jekt-a-fer) (ferric carboxymaltose injection) What is INJECTAFER ? INJECTAFER is a prescription iron replacement medicine used for the treatment of: iron deficiency anemia (IDA) in: adults and children 1 year of age and older who cannot tolerate iron taken by mouth (oral) or who have not responded well to oral iron . adults who have chronic kidney disease who are not on dialysis (non-dialysis dependent chronic kidney disease). iron deficiency in adults with mild to moderate heart failure to improve the ability to exercise (improve exercise capacity). It is not known if INJECTAFER is safe and effective in children with IDA who are under 1 year of age. It is not known if INJECTAFER is safe and effective in children with iron deficiency and mild to moderate heart failure to improve exercise capacity. Do not receive INJECTAFER. Do not receive INJECTAFER if you are allergic to ferric carboxymaltose or any of the ingredients in INJECTAFER. See the end of this Patient Information leaflet for a complete list of ingredients in INJECTAFER. Before receiving INJECTAFER, tell your healthcare provider about all of your medical conditions, including if you: have had an allergic reaction to iron given into your vein have a history of trouble absorbing certain vitamins or phosphate in your body have inflammatory bowel disease have hyperparathyroidism have low vitamin D levels have high blood pressure have previously received INJECTAFER are pregnant or plan to become pregnant. INJECTAFER may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with INJECTAFER. are breastfeeding or plan to breastfeed. INJECTAFER passes into your breast milk. It is not known if INJECTAFER will harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with INJECTAFER. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive INJECTAFER ? INJECTAFER is given into your vein (intravenously) by your healthcare provider. INJECTAFER is usually given in 2 doses at least 7 days apart for IDA, or 6 weeks apart for iron deficiency with mild to moderate heart failure to improve exercise capacity. If your healthcare provider decides it is right for you, INJECTAFER may be given intravenously by your healthcare provider as a single-dose treatment. INJECTAFER treatment may be repeated if your healthcare provider decides it is needed. What are the possible side effects of INJECTAFER? INJECTAFER may cause serious side effects, including: Allergic reactions. Serious life-threatening allergic reactions that can lead to death have happened in people who receive INJECTAFER and may include the following signs or symptoms: low blood pressure feeling dizzy or lightheaded loss of consciousness trouble breathing swelling fast heartbeat cold or clammy skin feet or hands turn blue itching rash hives wheezing Your healthcare provider will watch you during and for at least 30 minutes after you receive INJECTAFER. Tell your healthcare provider right away if you develop any signs or symptoms of allergic reactions during or after treatment with INJECTAFER. Symptoms of low blood phosphate levels . INJECTAFER may cause low levels of phosphate in your blood that may be serious and can lead to softening of your bones and broken bones (fractures), especially in people who have received multiple INJECTAFER treatments. Your healthcare provider may check your blood phosphate levels before a repeat treatment with INJECTAFER if you are at risk for low blood phosphate levels. If a repeat treatment is needed within 3 months of your last treatment your healthcare provider should check your blood phosphate levels. Tell your healthcare provider if you develop any of the following signs or symptoms of low blood phosphate levels during treatment with INJECTAFER: feeling very tired muscle weakness or pain bone or joint pain broken bones • High blood pressure. High blood pressure, sometimes with redness and warmth of the face (facial flushing), dizziness, or nausea, has happened during treatment with INJECTAFER. Your healthcare provider will check your blood pressure and check for any signs and symptoms of high blood pressure after you receive INJECTAFER. The most common side effects of INJECTAFER in adults include: nausea high blood pressure flushing injection site reactions skin redness low levels of phosphate in your blood dizziness The most common side effects of INJECTAFER in children include: low levels of phosphate in your blood injection site reactions rash headache vomiting These are not all the possible side effects of INJECTAFER. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of INJECTAFER . Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about INJECTAFER that is written for health professionals. What are the ingredients in INJECTAFER? Active ingredient: ferric carboxymaltose. Inactive ingredients: water for injection. Sodium hydroxide or hydrochloric acid may be added to adjust pH to 5.0-7.0. Distributed by : INJECTAFER is manufactured under license from Vifor (International) Inc, Switzerland. For more information go to www.injectafer.com or call 1-800-734-9236. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 05/2023 ARI logo"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Risk of hypersensitivity reactions which may have serious consequences for the fetus. ( 8.1 ) 8.1 Pregnancy Risk Summary Parenteral iron administration may be associated with hypersensitivity reactions [ see Warnings and Precautions ( 5.1 )], which may have serious consequences, such as fetal bradycardia ( see Clinical Considerations ). Advise pregnant women of the potential risk to a fetus. Published studies and available data from postmarketing reports with intravenous Injectafer are insufficient to assess the risk of major birth defects and miscarriage. There are risks to the mother and fetus associated with untreated IDA in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see Clinical Considerations). In animal reproduction studies, administration of ferric carboxymaltose to rabbits during the period of organogenesis caused adverse developmental outcomes including fetal malformations and increased implantation loss at maternally toxic doses of approximately 12% to 23% of the human weekly dose of 750 mg (based on body surface area). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Untreated IDA in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight. Fetal/Neonatal adverse reactions Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products (such as Injectafer) which may cause fetal bradycardia, especially during the second and third trimester. Data Human Data Published data from randomized controlled studies, prospective observational studies and retrospective studies on the use of ferric carboxymaltose in pregnant women have not reported an association with intravenous ferric carboxymaltose and major birth defects and miscarriage. However, these studies cannot establish or exclude the absence of any drug-related risk during pregnancy. Animal Data Administration of ferric carboxymaltose to rats as a one-hour intravenous infusion up to 30 mg/kg/day iron on gestation days 6 to 17 did not result in adverse embryonic or fetal findings. This daily dose in rats is approximately 40% of the human weekly dose of 750 mg based on body surface area. In rabbits, ferric carboxymaltose was administered as a one-hour infusion on gestation days 6 to 19 at iron doses of 4.5, 9, 13.5, and 18 mg/kg/day. Malformations were seen starting at the daily dose of 9 mg/kg (23% of the human weekly dose of 750 mg). Spontaneous abortions occurred starting at the daily iron dose of 4.5 mg/kg (12% of the human weekly dose of 750 mg based on body surface area). Pre-implantation loss was at the highest dose. Adverse embryonic or fetal effects were observed in the presence of maternal toxicity. A pre- and post-natal development study was conducted in rats at intravenous doses up to 18 mg/kg/day of iron (approximately 23% of the weekly human dose of 750 mg based on body surface area). There were no adverse effects on survival of offspring, their behavior, sexual maturation or reproductive parameters. 8.2 Lactation Risk Summary The available published data on the use of ferric carboxymaltose in lactating women demonstrate that iron is present in breast milk. Among the breastfed infants, adverse reactions included constipation and diarrhea but none of the adverse reactions reported were considered related to ferric carboxymaltose exposure through breastmilk. There is no information on the effects of ferric carboxymaltose on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Injectafer in addition to any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of Injectafer for IDA in pediatric patients aged 1 year and older who have normal kidney function and have either intolerance to oral iron or have had unsatisfactory response to oral iron have been established. Use of Injectafer for this indication in this age group is supported by evidence from adequate and well-controlled studies of Injectafer in adults with additional pharmacodynamic and safety data in pediatric patients aged 1 year and older [ see Adverse Reactions ( 6.1 ) and Clinical Pharmacology ( 12.3 )]. Safety and effectiveness of Injectafer have not been established in pediatric patients less than 1 year of age with IDA. Safety and effectiveness of Injectafer have not been established to improve exercise capacity in pediatric patients with ID and symptomatic heart failure. 8.5 Geriatric Use Of the 1,775 subjects in clinical studies of Injectafer, 50% were 65 years and over, while 25% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"dosage_and_administration_table":["
Weight less than 70 kgWeight 70 kg or more
Hb (g/dL) Hb (g/dL)
< 1010 to 14 > 14 to < 15 < 1010 to 14 > 14 to < 15
Day 11,000 mg 1,000 mg500 mg 1,000 mg1,000 mg 500 mg
Week 6 500 mg No dose No dose 1,000 mg 500 mgNo dose
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 2 ML CONTAINER LABEL NDC 0517-0602-01 Rx Only Injectafer ® (ferric carboxymaltose injection) 100 mg/2 mL (50 mg/mL) For Intravenous Use Only Single Dose Vial. Discard Unused Portion. AMERICAN REGENT, INC. SHIRLEY, NY 11967 2 mL Container Label","PRINCIPAL DISPLAY PANEL - 2 ML CARTON LABELING NDC 0517-0602-01 Injectafer ® (ferric carboxymaltose injection) 100 mg/2 mL (50 mg/mL) For Intravenous Use Only Single Dose Vial. Discard Unused Portion. Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 2 mL carton","PRINCIPAL DISPLAY PANEL - 15 ML CONTAINER LABEL NDC 0517-0650-01 Injectafer ® (ferric carboxymaltose injection) 750 mg/15 mL(50 mg/mL) FOR INTRAVENOUS USE ONLY Single Dose Vial. Discard Unused Portion. Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 Container Label","PRINCIPAL DISPLAY PANEL - 15 ML CARTON LABELING NDC 0517-0650-01 Injectafer ® (ferric carboxymaltose injection) 750 mg/15 mL (50 mg/mL) FOR INTRAVENOUS USE ONLY Single Dose Vial. Discard Unused Portion. Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 Carton Labeling","PRINCIPAL DISPLAY PANEL - 20 ML CONTAINER LABEL NDC 0517-0620-01 Rx Only Injectafer ® (ferric carboxymaltose injection) 1,000 mg/20 mL (50 mg/mL) FOR INTRAVENOUS USE ONLY Single-Dose Vial. Discard Unused Portion. AMERICAN REGENT, INC. SHIRLEY, NY 11967 20 mL Container Label","PRINCIPAL DISPLAY PANEL - 20 ML CARTON LABELING NDC 0517-0620-01 Injectafer ® (ferric carboxymaltose injection) 1,000 mg/20 mL (50 mg/mL) FOR INTRAVENOUS USE ONLY Single-Dose Vial. . Discard Unused Portion. Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 20 mL Carton","Serialization Label (2 mL) 2 mL Serialization Label","Serialization Label (15 mL) Serialization Label - 1 pack","Serialization Label (20 mL) 20 mL Serialization Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenicity studies have not been performed with ferric carboxymaltose. Ferric carboxymaltose was not genotoxic in the following genetic toxicology studies: in vitro microbial mutagenesis (Ames) assay, in vitro chromosome aberration test in human lymphocytes, in vitro mammalian cell mutation assay in mouse lymphoma L5178Y/TK+/- cells, in vivo mouse micronucleus test at single intravenous doses up to 500 mg/kg. In a combined male and female fertility study, ferric carboxymaltose was administered intravenously over one hour to male and female rats at iron doses of up to 30 mg/kg. Animals were dosed 3 times per week (on Days 0, 3, and 7). There was no effect on mating function, fertility or early embryonic development. Based on body surface area, the dose of 30 mg/kg in animals is approximately 40% of the human dose of 750 mg."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Iron deficiency anemia","category":"indication"},{"label":"Am Regent","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"HYPOPHOSPHATAEMIA","source":"FDA FAERS","actionTaken":"813 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"548 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"422 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"386 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"363 reports"},{"date":"","signal":"PRODUCT QUALITY ISSUE","source":"FDA FAERS","actionTaken":"323 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"303 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"290 reports"},{"date":"","signal":"URTICARIA","source":"FDA FAERS","actionTaken":"286 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"272 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"7.2%","severity":"common","_validated":true},{"effect":"Hypertension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Flushing","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site reactions","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Erythema","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypophosphatemia","drugRate":"2.1%","severity":"common","_validated":true},{"effect":"Dizziness","drugRate":"2.1%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"2.1%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"1.3%","severity":"mild","_validated":true},{"effect":"Dysgeusia","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Hepatic enzyme increased","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Injection site discoloration","drugRate":"1.4%","severity":"mild","_validated":true},{"effect":"Hypotension","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"0.5%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Gamma glutamyl transferase increased","drugRate":"reported","severity":"unknown"},{"effect":"Paresthesia","drugRate":"reported","severity":"unknown"},{"effect":"Sneezing","drugRate":"reported","severity":"unknown"},{"effect":"Nasopharyngitis","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal infections","drugRate":"reported","severity":"unknown"},{"effect":"Liver function test increased","drugRate":"reported","severity":"unknown"},{"effect":"Platelet count decreased","drugRate":"reported","severity":"unknown"},{"effect":"White blood cell count decreased","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Risk of hypersensitivity reactions which may have serious consequences for the fetus. Parenteral iron administration may be associated with hypersensitivity reactions see Warnings and Precautions (5.1)], which may have serious consequences, such as fetal bradycardia (see Clinical Considerations). Advise pregnant women of the potential risk to fetus. Published studies and available data from postmarketing reports with intravenous Injectafer are insufficient to assess the risk of major birth defects and miscarriage. There are risks to the mother and fetus associated with untreated IDA in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see Clinical Considerations).In animal reproduction studies, administration of ferric carboxymaltose to rabbits during the period of organogenesis caused adverse developmental outcomes including fetal malformations and increased implantation loss at maternally toxic doses of approximately 12% to 23% of the human weekly dose of 750 mg (based on body surface area). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Of the 1,775 subjects in clinical studies of Injectafer, 50% were 65 years and over, while 25% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"The safety and effectiveness of Injectafer for IDA in pediatric patients aged 1 year and older who have normal kidney function and have either intolerance to oral iron or have had unsatisfactory response to oral iron have been established. Use of Injectafer for this indication in this age group is supported by evidence from adequate and well-controlled studies of Injectafer in adults with additional pharmacodynamic and safety data in pediatric patients aged 1 year and older [see Additional information]."}},"trials":[],"aliases":[],"company":"Am Regent","patents":[{"applNo":"N203565","source":"FDA Orange Book","status":"Active","expires":"Jan 8, 2027","useCode":"U-1620","territory":"US","drugProduct":false,"patentNumber":"8895612","drugSubstance":false},{"applNo":"N203565","source":"FDA Orange Book","status":"Active","expires":"Feb 15, 2028","useCode":"U-1432","territory":"US","drugProduct":false,"patentNumber":"7754702","drugSubstance":false},{"applNo":"N203565","source":"FDA Orange Book","status":"Active","expires":"Jan 8, 2027","useCode":"U-3472","territory":"US","drugProduct":false,"patentNumber":"11478502","drugSubstance":false},{"applNo":"N203565","source":"FDA Orange Book","status":"Active","expires":"Jan 8, 2027","useCode":"U-3435","territory":"US","drugProduct":false,"patentNumber":"11433091","drugSubstance":false},{"applNo":"N203565","source":"FDA Orange Book","status":"Active","expires":"Jan 8, 2027","useCode":"U-3637","territory":"US","drugProduct":false,"patentNumber":"11364260","drugSubstance":false},{"applNo":"N203565","source":"FDA Orange Book","status":"Active","expires":"Feb 5, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7612109","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FERRIC CARBOXYMALTOSE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:27:13.865902+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:27:10.679570+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ferric Carboxymaltose","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:27:20.592259+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:27:19.055058+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:27:09.362296+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FERRIC CARBOXYMALTOSE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:27:19.355384+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:27:07.784413+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:27:07.784472+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:27:21.117755+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108597/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:27:20.083412+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA203565","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:27:07.784476+00:00"}},"allNames":"injectafer","offLabel":[],"synonyms":["ferric carboxymaltose","injectafer","iron dextri-maltose","ferinject"],"timeline":[{"date":"2013-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from LUITPOLD to Am Regent"},{"date":"2013-07-25","type":"positive","source":"DrugCentral","milestone":"FDA approval (Luitpold)"},{"date":"2019-03-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Zeria Pharmaceutical Co., Ltd.)"},{"date":"2026-05-31","type":"negative","source":"FDA Orange Book","milestone":"I-915 exclusivity expires"},{"date":"2027-02-05","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7612109 expires"}],"aiSummary":"Injectafer (FERRIC CARBOXYMALTOSE) is a small molecule medication originally developed by LUITPOLD and currently owned by Am Regent. It is used to treat iron deficiency anemia, a condition where the body does not have enough iron to produce healthy red blood cells. Injectafer works by providing a rapid increase in iron levels, which helps to alleviate symptoms of anemia such as fatigue and weakness. It is a patented medication with no generic manufacturers available. Key safety considerations include potential allergic reactions and interactions with other medications.","approvals":[{"date":"2013-07-25","orphan":false,"company":"LUITPOLD","regulator":"FDA"},{"date":"2019-03-26","orphan":false,"company":"ZERIA PHARMACEUTICAL CO., LTD.","regulator":"PMDA"}],"brandName":"Injectafer","ecosystem":[{"indication":"Iron deficiency anemia","otherDrugs":[{"name":"cyanocobalamin","slug":"cyanocobalamin","company":""},{"name":"docusate sodium","slug":"docusate-sodium","company":""},{"name":"ferric citrate","slug":"ferric-citrate","company":"Keryx Biopharms"},{"name":"ferric derisomaltose","slug":"ferric-derisomaltose","company":"Pharmacosmos As"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"Ferric carboxymaltose is colloidal iron (III) hydroxide in complex with carboxymaltose, carbohydrate polymer that releases iron.","oneSentence":"Injectafer works by providing a rapid increase in iron levels in the body.","technicalDetail":"Injectafer is a trivalent iron complex that is administered intravenously, providing a rapid increase in iron levels through a process called transferrin saturation, which helps to replenish iron stores and alleviate symptoms of anemia."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Iron_supplement","title":"Iron supplement","extract":"Iron supplements, also known as iron salts and iron pills, are a number of iron formulations used to treat and prevent iron deficiency including iron-deficiency anemia. For prevention they are only recommended in those with poor absorption, heavy menstrual periods, pregnancy, hemodialysis, or a diet low in iron. Prevention may also be used in low birth weight babies. They are taken by mouth, injection into a vein, or injection into a muscle. While benefits may be seen in days, up to two months may be required until iron levels return to normal.","wiki_history":"==History==\nThe first pills were commonly known as Blaud's pills, which were named after P. Blaud of Beaucaire, the French physician who introduced and started the use of these medications as a treatment for patients with anemia."},"commercial":{"launchDate":"2013","_launchSource":"DrugCentral (FDA 2013-07-25, LUITPOLD)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5128","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FERRIC%20CARBOXYMALTOSE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FERRIC CARBOXYMALTOSE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Iron_supplement","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:17:05.338310","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:27:24.771654+00:00","fieldsConflicting":4,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"exclusivity":[{"code":"I-915","date":"May 31, 2026"},{"code":"I-915","date":"May 31, 2026"},{"code":"I-915","date":"May 31, 2026"},{"code":"I-915","date":"May 31, 2026"}],"genericName":"ferric carboxymaltose","indications":{"approved":[{"name":"Iron deficiency anemia","source":"DrugCentral","snomedId":87522002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Am Regent","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00981045","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","status":"COMPLETED","sponsor":"American Regent, Inc.","isPivotal":true,"startDate":"2009-08","conditions":["Iron Deficiency Anemia","Impaired Renal Function"],"enrollment":2561,"completionDate":"2011-08"},{"nctId":"NCT00982007","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)","status":"COMPLETED","sponsor":"American Regent, Inc.","isPivotal":true,"startDate":"2009-09","conditions":["Iron Deficiency Anemia"],"enrollment":997,"completionDate":"2011-08"},{"nctId":"NCT07476859","phase":"PHASE4","title":"Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2026-03-05","conditions":["Acute Coronary Syndromes (ACS)","Iron Deficiencies","Elderly (People Aged 65 or More)"],"enrollment":538,"completionDate":"2028-05"},{"nctId":"NCT07414199","phase":"PHASE4","title":"The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Orange County","startDate":"2026-01-31","conditions":["Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease","Iron Deficiency Anaemia Due to Dietary Causes","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia Secondary to IBD or Gastric Bypass","Iron Deficiency Anemias"],"enrollment":150,"completionDate":"2026-12-31"},{"nctId":"NCT07384663","phase":"PHASE1","title":"EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY","status":"COMPLETED","sponsor":"Dr Salaha Azam","startDate":"2025-06-01","conditions":["Iron Deficiency Anaemia in Childbirth"],"enrollment":112,"completionDate":"2025-11-30"},{"nctId":"NCT07359599","phase":"PHASE4","title":"The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension","status":"RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2026-01-27","conditions":["Pulmonary Hypertension","Iron Deficiency"],"enrollment":306,"completionDate":"2028-10"},{"nctId":"NCT07370688","phase":"PHASE4","title":"Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-08-12","conditions":["Aortic Valve Stenosis","Iron Deficiency","TAVI(Transcatheter Aortic Valve Implantation)","Cardiovascular Diseases"],"enrollment":402,"completionDate":"2028-07"},{"nctId":"NCT07340450","phase":"NA","title":"Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia","status":"COMPLETED","sponsor":"Shahida Islam Medical Complex","startDate":"2025-02-18","conditions":["Postpartum Anaemia"],"enrollment":122,"completionDate":"2025-08-18"},{"nctId":"NCT03817957","phase":"PHASE3","title":"Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency","status":"COMPLETED","sponsor":"Prof. Dr. Frank Behrens","startDate":"2018-09-18","conditions":["Iron Deficiency Anemia"],"enrollment":187,"completionDate":"2024-10-21"},{"nctId":"NCT05309499","phase":"NA","title":"An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function","status":"COMPLETED","sponsor":"Kazan State Medical University","startDate":"2021-12-05","conditions":["Myocardial Infarction","Iron-deficiency"],"enrollment":298,"completionDate":"2025-09-15"},{"nctId":"NCT02632760","phase":"PHASE4","title":"Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery","status":"COMPLETED","sponsor":"Bayside Health","startDate":"2016-07-15","conditions":["Anaemia"],"enrollment":955,"completionDate":"2024-11-27"},{"nctId":"NCT05793996","phase":"PHASE4","title":"The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)","status":"RECRUITING","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2023-04-28","conditions":["Chronic Heart Failure","Iron Deficiency, Latent"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT06309641","phase":"","title":"Methemoglobinemia Following Intravenous Iron Treatment","status":"COMPLETED","sponsor":"Claudia Seiler","startDate":"2024-09-02","conditions":["Methemoglobinemia","Anemia","Iron Deficiencies","Side Effect"],"enrollment":50,"completionDate":"2025-10-13"},{"nctId":"NCT07217873","phase":"PHASE2,PHASE3","title":"IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-11-21","conditions":["Scoliosis Correction","Iron Deficiency","Transfusion Blood","Surgery Complications","Spinal Fusion","Scoliosis Idiopathic Adolescent","Scoliosis Neuromuscular"],"enrollment":120,"completionDate":"2027-10-31"},{"nctId":"NCT06958822","phase":"","title":"Ferric Carboxymaltose Methemoglobinemia Study","status":"COMPLETED","sponsor":"Ordu University","startDate":"2025-04-14","conditions":["Methemoglobinemia","Anemia, Iron-Deficiency","Parenteral Iron Therapy","Ferric Carboxymaltose"],"enrollment":977,"completionDate":"2025-09-30"},{"nctId":"NCT07115121","phase":"NA","title":"Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-02-02","conditions":["Anemia"],"enrollment":40,"completionDate":"2025-07-31"},{"nctId":"NCT04915820","phase":"NA","title":"Iron and COVID-19 Vaccine Response","status":"COMPLETED","sponsor":"Jomo Kenyatta University of Agriculture and Technology","startDate":"2021-05-29","conditions":["Iron Deficiency Anemia","Vaccine Response Impaired","COVID-19 Vaccine","Iron Deficiency Anemia Treatment"],"enrollment":121,"completionDate":"2021-09-09"},{"nctId":"NCT05636774","phase":"NA","title":"Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2022-12-12","conditions":["Patients With Advanced Cancer Receiving Specialized Palliative Care"],"enrollment":97,"completionDate":"2025-03-01"},{"nctId":"NCT04744181","phase":"","title":"Patient Blood Management In CARdiac sUrgical patientS","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-01-18","conditions":["Anemia","Blood Loss Anemia","Iron-deficiency","Iron Deficiency Anemia","Iron Deficiency Anemia Treatment","Erythropoiesis Abnormal"],"enrollment":479,"completionDate":"2022-01-31"},{"nctId":"NCT06994065","phase":"NA","title":"Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients","status":"RECRUITING","sponsor":"Sindh Institute of Urology and Transplantation","startDate":"2025-06-02","conditions":["Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease"],"enrollment":128,"completionDate":"2025-09"},{"nctId":"NCT06833788","phase":"PHASE4","title":"Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":["Postpartum Depression (PPD)"],"enrollment":2860,"completionDate":"2028-10"},{"nctId":"NCT05759078","phase":"PHASE4","title":"Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2022-09-22","conditions":["Myocardial Infarction, Acute"],"enrollment":1000,"completionDate":"2026-12-31"},{"nctId":"NCT07057973","phase":"NA","title":"The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-07-01","conditions":["Ferric Carboxymaltose"],"enrollment":100,"completionDate":"2026-07-01"},{"nctId":"NCT07053475","phase":"PHASE4","title":"IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches","status":"RECRUITING","sponsor":"Syed Hamza Mufarrih","startDate":"2025-04-02","conditions":["Heart Failure","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)","Iron Deficiency","Iron-deficiency Anemia (IDA)"],"enrollment":250,"completionDate":"2027-03-31"},{"nctId":"NCT01950247","phase":"PHASE4","title":"Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2013-08-15","conditions":["Iron Deficiency Anemia (IDA)"],"enrollment":1025,"completionDate":"2015-06"},{"nctId":"NCT03833336","phase":"PHASE3","title":"Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)","status":"COMPLETED","sponsor":"Institut de Recerca Biomèdica de Lleida","startDate":"2017-08-23","conditions":["Heart Failure With Normal Ejection Fraction","Ferropenic Anemia"],"enrollment":72,"completionDate":"2024-12-20"},{"nctId":"NCT06895993","phase":"PHASE1","title":"Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-04-07","conditions":["Healthy Adult"],"enrollment":84,"completionDate":"2025-05-08"},{"nctId":"NCT00685815","phase":"PHASE2","title":"Intravenous Iron Metabolism in Restless Legs Syndrome","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2006-11","conditions":["Restless Legs"],"enrollment":12,"completionDate":"2012-12"},{"nctId":"NCT06948864","phase":"","title":"Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia","status":"COMPLETED","sponsor":"Hospital Universitario Infanta Cristina","startDate":"2020-01-01","conditions":["Anemia","Anemia (Iron-Loading)","Perioperative Bleeding","Infection Prevention","Readmission, Hospital","Surgical Complication","Length of Hospital Stay","Iron Deficiency Anemia Treatment","Prehabilitation"],"enrollment":152,"completionDate":"2024-12-31"},{"nctId":"NCT05816265","phase":"PHASE4","title":"Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"Radha Gopalan","startDate":"2024-01-24","conditions":["Heart Failure","Iron-deficiency"],"enrollment":40,"completionDate":"2027-03"},{"nctId":"NCT00740246","phase":"PHASE3","title":"Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2005-07","conditions":["Anemia"],"enrollment":594,"completionDate":"2006-05"},{"nctId":"NCT05545527","phase":"","title":"Neuroimaging Ancillary Study","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2023-02-21","conditions":["Iron Deficiency Anemia","Iron Deficiency Anemia of Pregnancy","Neurodevelopmental Disorder of Foetus","Iron Deficiency Anemia Treatment","Fetal Neurodevelopmental Disorder","Child Development"],"enrollment":184,"completionDate":"2025-04-07"},{"nctId":"NCT04343170","phase":"NA","title":"Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-09-01","conditions":["Ultra-short-term","Iron Deficiency Anemia","Scoliosis Idiopathic"],"enrollment":44,"completionDate":"2024-10-01"},{"nctId":"NCT04625530","phase":"PHASE3","title":"Perioperative Management in Gynaecological Carcinoma Surgery","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-08-01","conditions":["Gynaecological Carcinoma"],"enrollment":0,"completionDate":"2026-12-31"},{"nctId":"NCT02826681","phase":"PHASE2","title":"Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia","status":"TERMINATED","sponsor":"American Regent, Inc.","startDate":"2017-07-10","conditions":["Restless Legs Syndrome (RLS)"],"enrollment":70,"completionDate":"2022-07-01"},{"nctId":"NCT06911034","phase":"PHASE4","title":"Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women","status":"COMPLETED","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2024-02-01","conditions":["Iron Deficiency Anemia (IDA)","Pregnancy"],"enrollment":60,"completionDate":"2024-09-30"},{"nctId":"NCT06686693","phase":"PHASE4","title":"Intravenous Iron Effects on Performance at High Altitude","status":"RECRUITING","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2022-04-15","conditions":["Hypoxia"],"enrollment":24,"completionDate":"2025-09-30"},{"nctId":"NCT05060731","phase":"PHASE4","title":"Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"University of Pecs","startDate":"2025-09-01","conditions":["GastroIntestinal Bleeding","Anemia"],"enrollment":570,"completionDate":"2028-02-01"},{"nctId":"NCT06080893","phase":"PHASE4","title":"The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2023-10-10","conditions":["Hip Fractures","Anemia","Complication,Postoperative"],"enrollment":209,"completionDate":"2025-03-24"},{"nctId":"NCT06883201","phase":"","title":"Application of Patient Blood Management in the Oncology Patient Affected by Breast Cancer","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2023-01-31","conditions":["Breast Cancer"],"enrollment":78,"completionDate":"2025-06-30"},{"nctId":"NCT06437080","phase":"NA","title":"Hypoferritinemia Without Anemia Among Reproductive Age Females","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akram Medical Complex","startDate":"2022-10-10","conditions":["Hypoferritenemia Without Anemia (HWA)","Iron Deficiency Without Anemia)"],"enrollment":1331,"completionDate":"2025-04"},{"nctId":"NCT03680456","phase":"PHASE4","title":"Postoperative Replacement of Intraoperative Iron Losses","status":"COMPLETED","sponsor":"Kepler University Hospital","startDate":"2020-03-06","conditions":["Blood Loss Anemia"],"enrollment":134,"completionDate":"2025-01-31"},{"nctId":"NCT03036462","phase":"PHASE4","title":"Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-03-07","conditions":["Systolic Heart Failure","Iron Deficiency"],"enrollment":1105,"completionDate":"2024-05-02"},{"nctId":"NCT03231085","phase":"NA","title":"Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-10-31","conditions":["Craniosynostosis"],"enrollment":100,"completionDate":"2024-10-03"},{"nctId":"NCT05744219","phase":"PHASE3","title":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","status":"RECRUITING","sponsor":"Jon Unosson","startDate":"2024-09-04","conditions":["Surgery","Liver Metastases","Liver Cancer","Pancreas Cancer","Aortic Aneurysm"],"enrollment":338,"completionDate":"2028-03-30"},{"nctId":"NCT04087993","phase":"PHASE3","title":"Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients","status":"WITHDRAWN","sponsor":"Dr. Frank Behrens","startDate":"2020-05-15","conditions":["Iron Deficiency Anemia"],"enrollment":0,"completionDate":"2020-12-31"},{"nctId":"NCT03769441","phase":"PHASE3","title":"Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-08-02","conditions":["Iron-deficiency","Transplant-Related Disorder"],"enrollment":148,"completionDate":"2024-08-19"},{"nctId":"NCT06350955","phase":"PHASE4","title":"IV Iron-induced Hypophosphatemia After RYGB","status":"RECRUITING","sponsor":"Lucie Favre","startDate":"2024-05-02","conditions":["Hypophosphatemia","Roux-en-Y Gastric Bypass"],"enrollment":94,"completionDate":"2026-06"},{"nctId":"NCT06542393","phase":"PHASE2","title":"PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)","status":"RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2024-06-01","conditions":["Anemia","Coronary Disease","Coronary Artery Disease","Coronary Stenosis","Coronary Occlusion","Systemic Inflammatory Response","Bleeding","Epigenetic Disorder"],"enrollment":120,"completionDate":"2026-06-01"},{"nctId":"NCT03037931","phase":"PHASE3","title":"Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2017-03-15","conditions":["Heart Failure","Iron-deficiency"],"enrollment":3065,"completionDate":"2023-02-02"},{"nctId":"NCT06442111","phase":"NA","title":"The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy","status":"NOT_YET_RECRUITING","sponsor":"Seoul St. Mary's Hospital","startDate":"2024-07-01","conditions":["Pancreaticojuodenectomy"],"enrollment":106,"completionDate":"2025-12-31"},{"nctId":"NCT06434025","phase":"PHASE3","title":"IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-05-24","conditions":["Heart Failure, Systolic","Iron Deficiencies"],"enrollment":99,"completionDate":"2026-11-24"},{"nctId":"NCT03074591","phase":"PHASE4","title":"Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2017-08-01","conditions":["Iron-deficiency","Heart Failure"],"enrollment":40,"completionDate":"2024-04-10"},{"nctId":"NCT05358509","phase":"PHASE4","title":"Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2021-03-15","conditions":["Iron Deficiency Anemia","Infant, Low Birth Weight","Anemia of Pregnancy"],"enrollment":4368,"completionDate":"2024-01-21"},{"nctId":"NCT06080555","phase":"PHASE1","title":"Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2023-10-09","conditions":["Iron Deficiency","Anaemia"],"enrollment":84,"completionDate":"2024-03-22"},{"nctId":"NCT04653181","phase":"NA","title":"Preoperative i.v. Iron Substitution in Patients With Colon Cancer","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2020-10-01","conditions":["Colon Cancer"],"enrollment":514,"completionDate":"2025-12-31"},{"nctId":"NCT05226169","phase":"PHASE3","title":"Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2022-04-29","conditions":["Advanced Gastric Carcinoma"],"enrollment":330,"completionDate":"2024-11-30"},{"nctId":"NCT03991000","phase":"PHASE3","title":"Iron in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Dr. med. Mahir Karakas","startDate":"2019-02-28","conditions":["Cardiovascular Diseases","Anemia, Iron-deficiency","Acute Myocardial Infarction","Atrial Fibrillation","Systolic Heart Failure"],"enrollment":8,"completionDate":"2021-12-15"},{"nctId":"NCT05702970","phase":"PHASE4","title":"Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2024-01-15","conditions":["Heart Failure","Iron-deficiency","Heart Failure, Systolic","Heart Failure NYHA Class II","Heart Failure NYHA Class III","Vitamin D Deficiency"],"enrollment":258,"completionDate":"2025-10-31"},{"nctId":"NCT05504863","phase":"","title":"RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2022-10-11","conditions":["Iron Deficiency Anemia","Neurodevelopmental Abnormality","Autism Spectrum Disorder"],"enrollment":538,"completionDate":"2026-01"},{"nctId":"NCT06061393","phase":"PHASE4","title":"Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2023-10-30","conditions":["Anemia, Iron Deficiency","Pregnancy Anemia"],"enrollment":200,"completionDate":"2025-09-20"},{"nctId":"NCT02694978","phase":"PHASE3","title":"A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)","status":"COMPLETED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2016-02-29","conditions":["Iron Deficiency Anemia"],"enrollment":2014,"completionDate":"2017-07-17"},{"nctId":"NCT04976179","phase":"PHASE3","title":"Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON)","status":"COMPLETED","sponsor":"University of Lagos, Nigeria","startDate":"2021-08-09","conditions":["Iron Deficiency Anemia of Pregnancy"],"enrollment":1056,"completionDate":"2023-06-15"},{"nctId":"NCT03218384","phase":"PHASE2","title":"Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2017-09-07","conditions":["Iron-deficiency"],"enrollment":20,"completionDate":"2022-04-04"},{"nctId":"NCT05098249","phase":"PHASE4","title":"Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia","status":"COMPLETED","sponsor":"Donat R. Spahn","startDate":"2021-11-11","conditions":["Anemia","Iron-deficiency","Hypophosphatemia"],"enrollment":92,"completionDate":"2023-05-23"},{"nctId":"NCT05187637","phase":"","title":".Patient Blood Management Program in Liver Transplantation","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2022-03-23","conditions":["Iron Deficiency Anemia"],"enrollment":66,"completionDate":"2023-04-24"},{"nctId":"NCT04355130","phase":"","title":"Autologous Tansfusion REquirements in Bone MArrow Harvest: The ATREMA Study","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-03-20","conditions":["Bone Marrow Donors"],"enrollment":7,"completionDate":"2022-12-20"},{"nctId":"NCT05708170","phase":"PHASE4","title":"Impact of Intravenous Iron on Musculoskeletal Function in Older Adults","status":"NOT_YET_RECRUITING","sponsor":"Liverpool Hope University","startDate":"2023-01","conditions":["Iron Deficiency Anemia"],"enrollment":100,"completionDate":"2027-01"},{"nctId":"NCT04968379","phase":"PHASE2","title":"Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia","status":"WITHDRAWN","sponsor":"American Regent, Inc.","startDate":"2022-07-21","conditions":["Iron Deficiency, Anaemia"],"enrollment":0,"completionDate":"2024-12-12"},{"nctId":"NCT05669872","phase":"NA","title":"Patient Blood Mangement (PBM) Using IV Iron in Patients With Gynecologic Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2023-02","conditions":["Gynecologic Cancer"],"enrollment":334,"completionDate":"2025-12"},{"nctId":"NCT04083755","phase":"PHASE4","title":"Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD)","status":"UNKNOWN","sponsor":"Biobizkaia Health Research Institute","startDate":"2019-08-15","conditions":["Anemia","Peripheral Arterial Occlusive Disease"],"enrollment":240,"completionDate":"2025-12-31"},{"nctId":"NCT05000853","phase":"","title":"New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2021-08-01","conditions":["Heart Failure"],"enrollment":210,"completionDate":"2023-08-01"},{"nctId":"NCT04141631","phase":"NA","title":"Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2020-01-13","conditions":["Cardiac Surgery","Transfusion","Perioperative Anemia"],"enrollment":128,"completionDate":"2022-06-15"},{"nctId":"NCT05581420","phase":"NA","title":"Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-06-02","conditions":["Inflammatory Bowel Diseases"],"enrollment":152,"completionDate":"2025-05"},{"nctId":"NCT03632525","phase":"PHASE4","title":"Intravenous Iron in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-02-22","conditions":["Cystic Fibrosis","Iron-deficiency"],"enrollment":20,"completionDate":"2021-10-26"},{"nctId":"NCT01975272","phase":"PHASE4","title":"The Use of Iron Therapy for Patients With Anemia After Caesarean Section","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2015-03-02","conditions":["Postoperative Anaemia"],"enrollment":27,"completionDate":"2018-06-21"},{"nctId":"NCT05505006","phase":"PHASE4","title":"Management of Preoperative Anaemia in Surgical Oncology","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-03-02","conditions":["Anemia","Tumor"],"enrollment":500,"completionDate":"2024-08-13"},{"nctId":"NCT03388385","phase":"PHASE4","title":"Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD","status":"UNKNOWN","sponsor":"Carol Davila University of Medicine and Pharmacy","startDate":"2017-09-20","conditions":["Renal Anemia","Iron Toxicity","Oxidative Stress","Endothelial Dysfunction"],"enrollment":40,"completionDate":"2022-12-20"},{"nctId":"NCT03541213","phase":"NA","title":"Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2019-01-23","conditions":["Iron-deficiency","Valvular Heart Disease"],"enrollment":55,"completionDate":"2020-09-07"},{"nctId":"NCT05477498","phase":"PHASE4","title":"Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction","status":"WITHDRAWN","sponsor":"Cantonal Hosptal, Baselland","startDate":"2021-12-01","conditions":["Heart Failure With Normal Ejection Fraction","Iron-deficiency"],"enrollment":0,"completionDate":"2022-12-31"},{"nctId":"NCT02410213","phase":"PHASE2","title":"A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2015-02-19","conditions":["Iron Deficiency Anemia (IDA)"],"enrollment":35,"completionDate":"2017-06-01"},{"nctId":"NCT02308449","phase":"NA","title":"Iron Status and Human Metabolism","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-10","conditions":["Iron Deficiency"],"enrollment":29,"completionDate":"2016-01"},{"nctId":"NCT03957057","phase":"PHASE3","title":"Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2020-09-10","conditions":["Postpartum Anemia Nos","Iron-deficiency"],"enrollment":300,"completionDate":"2022-06-15"},{"nctId":"NCT05429749","phase":"PHASE4","title":"Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-07-30","conditions":["Hip Fractures"],"enrollment":264,"completionDate":"2024-12-31"},{"nctId":"NCT03523117","phase":"PHASE3","title":"Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2019-01-31","conditions":["Iron Deficiency Anemia"],"enrollment":79,"completionDate":"2021-01-29"},{"nctId":"NCT01100879","phase":"PHASE4","title":"Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy","status":"TERMINATED","sponsor":"Vifor Pharma","startDate":"2010-03","conditions":["Iron-Deficiency Anemia"],"enrollment":3,"completionDate":"2011-10"},{"nctId":"NCT04269707","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2019-11-19","conditions":["Iron Deficiency Anemia"],"enrollment":7,"completionDate":"2021-01-29"},{"nctId":"NCT01447628","phase":"PHASE2","title":"IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-03-29","conditions":["Pulmonary Arterial Hypertension","Iron Deficiency"],"enrollment":56,"completionDate":"2017-12-22"},{"nctId":"NCT04862715","phase":"PHASE4","title":"The Iron and Muscle Study","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2019-04-26","conditions":["CKD Stage 3","CKD Stage 4","Iron-deficiency"],"enrollment":75,"completionDate":"2022-02-21"},{"nctId":"NCT05114278","phase":"PHASE4","title":"Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-02-15","conditions":["Celiac Disease"],"enrollment":204,"completionDate":"2026-04-15"},{"nctId":"NCT04246021","phase":"NA","title":"Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy","status":"COMPLETED","sponsor":"King Hussein Cancer Center","startDate":"2016-06-15","conditions":["Anemia","Cancer"],"enrollment":84,"completionDate":"2017-12-31"},{"nctId":"NCT00520780","phase":"PHASE3","title":"Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2007-04","conditions":["Chronic Heart Failure","Iron Deficiency","Iron Deficiency Anemia","Anaemia"],"enrollment":456,"completionDate":"2009-09"},{"nctId":"NCT02397057","phase":"PHASE3","title":"Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2015-01","conditions":["Restless Legs Syndrome (RLS)"],"enrollment":209,"completionDate":"2018-01"},{"nctId":"NCT03759964","phase":"PHASE4","title":"Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery","status":"COMPLETED","sponsor":"St Joseph University, Beirut, Lebanon","startDate":"2018-12-15","conditions":["Anemia, Iron Deficiency"],"enrollment":194,"completionDate":"2021-01-02"},{"nctId":"NCT04631679","phase":"","title":"Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2019-11-08","conditions":["Anemia","Anemia, Iron Deficiency","Iron Deficiency Anemia Treatment"],"enrollment":23,"completionDate":"2021-04-29"},{"nctId":"NCT04912661","phase":"NA","title":"Iron and Vaccine Response","status":"COMPLETED","sponsor":"Swiss Federal Institute of Technology","startDate":"2021-05-29","conditions":["Iron Deficiency Anemia","Vaccine Preventable Disease","Vaccine Response Impaired","Iron Deficiency Anemia Treatment"],"enrollment":121,"completionDate":"2021-09-09"},{"nctId":"NCT03380520","phase":"PHASE4","title":"Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2017-10-01","conditions":["Heart Failure"],"enrollment":75,"completionDate":"2021-08-04"},{"nctId":"NCT04974021","phase":"","title":"Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-06-20","conditions":["Ferric Carboxymaltose","Heart Failure With Reduced Ejection Fraction","Arrhythmias, Cardiac"],"enrollment":106,"completionDate":"2021-09-30"},{"nctId":"NCT02937454","phase":"PHASE4","title":"Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency","status":"COMPLETED","sponsor":"Vifor (International) Inc.","startDate":"2017-04-03","conditions":["Iron Deficiency","Heart Failure"],"enrollment":1132,"completionDate":"2020-07-21"},{"nctId":"NCT03591406","phase":"PHASE3","title":"To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Vifor (International) Inc.","startDate":"2017-07-03","conditions":["Iron Deficiency Anemia"],"enrollment":371,"completionDate":"2019-02-25"},{"nctId":"NCT04898569","phase":"PHASE4","title":"Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-02-10","conditions":["Coronary Artery Disease"],"enrollment":100,"completionDate":"2022-12-31"},{"nctId":"NCT02453334","phase":"PHASE3","title":"Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2015-05-23","conditions":["Cancer and Chemotherapy Related Anemia"],"enrollment":244,"completionDate":"2018-01-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT00982007","NCT00981045"],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Injectafer"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"204720","NDDF":"012722","UNII":"6897GXD6OE","VANDF":"4032651","INN_ID":"8853","RXNORM":"1433693","UMLSCUI":"C2001867","chemblId":"CHEMBL2108597","ChEMBL_ID":"CHEMBL2108597","KEGG_DRUG":"D08920","DRUGBANK_ID":"DB08917","PUBCHEM_CID":"86278165","SNOMEDCT_US":"430077004","SECONDARY_CAS_RN":"1461680-64-7","MESH_SUPPLEMENTAL_RECORD_UI":"C522335"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2013-","companyName":"Luitpold","relationship":"Original Developer"},{"period":"present","companyName":"Am Regent","relationship":"Current Owner"},{"period":"2019","companyName":"Zeria Pharmaceutical Co., Ltd.","relationship":"PMDA Licensee"}],"publicationCount":1000,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"originalDeveloper":"Luitpold","recentPublications":[{"date":"2026 Mar 25","pmid":"41881665","title":"Parenteral iron-Does it increase infection risk?","journal":"Vox sanguinis"},{"date":"2026 Mar 18","pmid":"41865415","title":"Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial.","journal":"The Lancet. Global health"},{"date":"2026 Mar 18","pmid":"41849242","title":"Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia.","journal":"Blood"},{"date":"2026","pmid":"41808693","title":"Integrating a single-dose intravenous iron therapy (ferric carboxymaltose) for maternal anaemia in Nigeria: Insights from stakeholder engagement.","journal":"Journal of public health in Africa"},{"date":"2026 Feb","pmid":"41771608","title":"Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study.","journal":"Nefrologia"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Am Regent","companyId":"am-regent","modality":"Small Molecule","firstApprovalDate":"2013","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-07-25T00:00:00.000Z","mah":"LUITPOLD","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-11-16T00:00:00.000Z","mah":"AM REGENT","brand_name_local":null,"application_number":"NDA203565"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2019-03-26T00:00:00.000Z","mah":"ZERIA PHARMACEUTICAL CO., LTD.","brand_name_local":null,"application_number":""},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:27:24.771654+00:00","fieldsConflicting":4,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}